Abstract:

Recently， targeted drugs are widely used in the treatment of advanced non-small cell lung cancer（NSCLC） patients with EGFR mutation. The detection of EGFR mutation status before treatment becomes important premise of individualized treatment. Now the detection of EGFR mutation mainly uses tissue examination as gold standard. Meanwhile using peripheral blood and cytology to detect EGFR mutation have been well developed. The qualitative and quantitative detection of EGFR mutations would be useful for predicting treatment response， monitoring disease progression and early detection of treatment failure associated with acquired drug resistance.